Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Chemoradiation in Recurrent/Metastatic HNSCC
NCT03424291Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03424291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424291.